Latest Breaking News On - Professor lin shen - Page 1 : comparemela.com

Supplemental New Drug Application for Akeso s Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer

/PRNewswire/ Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA).

Lin shenHong kongJi jiafuYu xiaAkeso incChina national medical products administrationUniversity cancer hospitalProfessor ji jiafuPeking university cancerProfessor lin shenSummit therapeuticsMain boardStock exchange

Qilu Pharmaceutical Announces Results from Phase I Clinical Study for Its Novel Bispecific Antibody QLS31905 at ESMO Immuno-Oncology Congress

/PRNewswire/ During the ESMO Immuno-Oncology Congress 2023 held in Geneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest.

Lin shenQilu pharmaceutical co ltdOncology congressUniversity cancer hospitalQilu pharmaceuticalProfessor lin shenPeking university cancerQilu pharmaceutical co

Qilu Pharmaceutical Announces Results From Phase I Clinical Study For Its Novel Bispecific Antibody QLS31905 At ESMO Immuno-Oncology Congress

Qilu Pharmaceutical Announces Results From Phase I Clinical Study For Its Novel Bispecific Antibody QLS31905 At ESMO Immuno-Oncology Congress
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Lin shenUniversity cancer hospitalQilu pharmaceutical co ltdOncology congressQilu pharmaceuticalProfessor lin shenPeking university cancer

Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18 2 Positive Gastric Cancer at ESMO Con

Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18 2 Positive Gastric Cancer at ESMO Con
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLin shenLos angelesCaroline germaTranscenta holdingProduct development centerClinical development centers in princetonTranslational research centerGroup headquartersPrnewswire transcenta holding limitedGlobal medicine developmentEuropean society for medical oncologyHealth authorityTranscenta immune tolerance breaking technologyHolding limitedEuropean society

Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy

Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy - read this article along with other careers information, tips and advice on BioSpace

Qing chenYong yueUnited statesHong kongRhui zhouDada chenLin shenInnovent biologicsWei caoEli lillyJacques ferlayAdimab incyteRebeccal siegelYi wen yuPrnewswire innovent biologics incDepartment of chemoradiotherapy oncology